Mohanjit Jolly - 15 Aug 2025 Form 4 Insider Report for Vyome Holdings, Inc (RSLS)

Role: Director
Signature: /s/ Mohanjit Jolly
Issuer symbol: RSLS
Transactions as of: 15 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 18 Nov 2025, 18:45:47 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Jolly Mohanjit	Director	HARVARD SQUARE,, ONE MIFFLIN PLACE, SUITE 400, CAMBRIDGE	/s/ Mohanjit Jolly	18 Nov 2025	0001867575

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HIND	Common Stock	Award		+454,456			454,456	15 Aug 2025	See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.
F2	Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.

Content

Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.